thevaccinereaction--2020-12-20--Peruvian Man Suffers Guillain-Barré-like Symptoms After Receiving Sinopharm COVID-19 Vaccine

On Dec. 11 , 2020 , Peru ’ s National Institute of Health ( INS ) said it was temporarily suspending the Phase 1 clinical trial of an experimental COVID-19 vaccine developed by Sinopharm Group Co. Ltd. of Shanghai , China after one of the participants in the trial who got the vaccine showed difficulty in moving his arms and legs—symptoms of Guillain-Barré syndrome ( GBS ) .1 2 3 4 5 In a public statement , the INS said that the “ adverse event ” was “ under investigation to determine if it is related to the vaccine or @ @ @ @ @ @ @ 5 “ Several days ago we signaled , as we are required , to the regulatory authorities that one of our participants ( in trials ) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome , ” said German Malaga , MD , chief researcher at Cayetano Heredia University in Lima , Peru , where the vaccine trial is being conducted .
“ We are concerned about the situation , and we are providing all of our help and support to ensure that it is cleared up , ” he @ @ @ @ @ @ @ part of a campaign by the U.S. government to vaccinate Americans against a novel type A strain of the influenza virus known as H1N1 ( “ swine flu ” ) , 450 people in the United States developed Guillain-Barre syndrome ( GBS ) , which involved inflammation of the peripheral nervous system and can cause temporary or permanent paralysis that can be fatal.1 2 6 According to referenced information on the website of the National Vaccine Information Center ( NVIC ) at NVIC.org : NVIC notes that GBS is characterized by “ muscle @ @ @ @ @ @ @ tingling , pain.
” It can cause “ paralysis of the face or one or more limbs ” and can take “ several months for recovery or it can leave the affected person with chronic health problems and disability.
” 7 The U.S. Food and Drug Administration ( FDA ) lists GBS as one of 22 possible “ adverse events outcomes ” that are being monitored after people receive new COVID-19 vaccinations.8 The other vaccine adverse events on the FDA ’ s surveillance list include : Unlike COVID-19 vaccines produced by companies such @ @ @ @ @ @ @ BioNTech SE ) and Moderna , Inc. that rely on a novel vaccine technology that uses synthetic messenger RNA ( mRNA ) designed to instruct cells in the human body to produce proteins and stimulate the production of SARS CoV-2 antibodies , Sinopharm ’ s COVID-19 vaccine uses traditional vaccine technology incorporating a killed SARS CoV-2 virus to deliver the vaccine.9 Peruvian health minister Pilar Mazzetti , MD announced on Dec. 16 that Sinopharm could resume its clinical trial in Peru even though it was unclear why the trial volunteer developed GBS .
@ @ @ @ @ @ @ Sinopharm and the suspension has been lifted , ” Dr. Mazzeti said.10